NZ601677A - Improved cancer therapy based on tumor associated antigens derived from cyclin d1 - Google Patents

Improved cancer therapy based on tumor associated antigens derived from cyclin d1

Info

Publication number
NZ601677A
NZ601677A NZ60167711A NZ60167711A NZ601677A NZ 601677 A NZ601677 A NZ 601677A NZ 60167711 A NZ60167711 A NZ 60167711A NZ 60167711 A NZ60167711 A NZ 60167711A NZ 601677 A NZ601677 A NZ 601677A
Authority
NZ
New Zealand
Prior art keywords
cyclin
cancer therapy
associated antigens
tumor associated
therapy based
Prior art date
Application number
NZ60167711A
Other languages
English (en)
Inventor
Steffen Walter
Toni Weinschenk
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of NZ601677A publication Critical patent/NZ601677A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ60167711A 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1 NZ601677A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35073110P 2010-06-02 2010-06-02
GB201009222A GB201009222D0 (en) 2010-06-02 2010-06-02 Improved cancer therapy based on tumour associated antigens derived from cyclin D1
PCT/EP2011/059121 WO2011151403A1 (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1

Publications (1)

Publication Number Publication Date
NZ601677A true NZ601677A (en) 2015-01-30

Family

ID=42471037

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60167711A NZ601677A (en) 2010-06-02 2011-06-01 Improved cancer therapy based on tumor associated antigens derived from cyclin d1

Country Status (17)

Country Link
US (2) US9023803B2 (enExample)
EP (1) EP2575850A1 (enExample)
JP (1) JP2013536157A (enExample)
KR (1) KR20130089175A (enExample)
CN (1) CN102971003A (enExample)
AU (1) AU2011260277B2 (enExample)
BR (1) BR112012030479A2 (enExample)
CA (1) CA2793601A1 (enExample)
EA (1) EA201291195A1 (enExample)
GB (1) GB201009222D0 (enExample)
MX (1) MX2012013998A (enExample)
MY (1) MY162741A (enExample)
NZ (1) NZ601677A (enExample)
PH (1) PH12012501898A1 (enExample)
SG (1) SG185353A1 (enExample)
UA (1) UA110473C2 (enExample)
WO (1) WO2011151403A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CN103848891B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Ccnd1自身抗体识别的抗原多肽
RU2687144C2 (ru) * 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
HRP20192262T1 (hr) 2013-08-05 2020-03-06 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
JP2018518956A (ja) 2015-06-19 2018-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
RS61203B1 (sr) 2015-07-06 2021-01-29 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jednjaka i drugih malignih tumora
HK1258386A1 (zh) 2015-10-05 2019-11-08 Immatics Biotechnologies Gmbh 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN114028549A (zh) 2016-02-19 2022-02-11 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
IL302705A (en) * 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN112553336B (zh) * 2020-12-17 2023-07-21 兰州大学 Snp在乳腺癌化疗耐药性检测领域的应用及其检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2004267506A1 (en) 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ES2319286T3 (es) 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
PL1760089T3 (pl) * 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
UA103882C2 (uk) 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
US20100310640A1 (en) * 2007-11-01 2010-12-09 Knutson Keith L Hla-dr binding peptides and their uses
NO2119726T3 (enExample) * 2008-05-14 2015-05-23
CA2754743C (en) * 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1

Also Published As

Publication number Publication date
EA201291195A1 (ru) 2014-06-30
MX2012013998A (es) 2013-01-28
US9056069B2 (en) 2015-06-16
CA2793601A1 (en) 2011-12-08
BR112012030479A2 (pt) 2017-01-24
CN102971003A (zh) 2013-03-13
GB201009222D0 (en) 2010-07-21
UA110473C2 (uk) 2016-01-12
US20120027684A1 (en) 2012-02-02
US9023803B2 (en) 2015-05-05
EP2575850A1 (en) 2013-04-10
JP2013536157A (ja) 2013-09-19
MY162741A (en) 2017-07-15
PH12012501898A1 (en) 2019-07-10
AU2011260277A1 (en) 2012-08-30
US20130177525A1 (en) 2013-07-11
KR20130089175A (ko) 2013-08-09
AU2011260277B2 (en) 2015-01-15
WO2011151403A1 (en) 2011-12-08
SG185353A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
PH12016500619A1 (en) Dry powder inhaler
NZ608502A (en) Polypeptides that bind to human complement component c5
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ714963A (en) Compositions and methods for treating anemia
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2015049688A3 (en) Patient-specific immunotherapy for treating heterogeneous tumors
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
UA115250C2 (uk) Фармацевтичні комбінації
CY1118430T1 (el) Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου
MX341547B (es) Péptidos pan-antivirales para la inhibición de proteína quinasa.
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
RU2013149175A (ru) Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE POSTPONEMENT PERIOD HAS BEEN CORRECTED TO 18

Effective date: 20130108

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2016 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20150617

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 JUN 2017 BY PAVIS EG

Effective date: 20160517

LAPS Patent lapsed